PRTA
Company Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.68M | 135.16M | 91.37M | 53.91M | 200.58M | 853,000 | 814,000 | 955,000 | 27.52M | 1.05M | 1.61M | 50.85M |
| Net Income | (244.09M) | (122.31M) | (147.03M) | (116.95M) | 66.97M | (111.14M) | (77.68M) | (155.65M) | (153.24M) | (160.11M) | (80.61M) | (7.15M) |
| EPS | -4.53 | -2.27 | -2.76 | -2.47 | 1.51 | -2.78 | -1.95 | -3.93 | -4.07 | -4.66 | -2.66 | -0.29 |
| Free Cash Flow | (163.72M) | (150.35M) | (136.72M) | (109.28M) | 92.03M | (80.56M) | (53.52M) | (30.04M) | (134.81M) | (133.91M) | N/A | N/A |
| FCF / Share | -3.04 | -2.80 | -2.57 | -2.31 | 2.08 | -2.02 | -1.34 | -0.76 | -3.58 | -3.90 | N/A | N/A |
| Operating CF | (163.58M) | (150.05M) | (133.91M) | (108.82M) | 92.61M | (80.36M) | (52.97M) | (28.28M) | (131.18M) | (117.27M) | N/A | N/A |
| Total Assets | 326.80M | 547.11M | 696.38M | 758.03M | 609.37M | 332.98M | 419.27M | 498.80M | 496.33M | 459.98M | N/A | N/A |
| Total Debt | 13.86M | 10.84M | 11.84M | 6.47M | 12.33M | 17.84M | 22.94M | 51.55M | 52.25M | 51.32M | N/A | N/A |
| Cash & Equiv | 307.53M | 471.39M | 618.83M | 710.41M | 579.09M | 295.38M | 375.72M | 427.66M | 417.62M | 386.92M | N/A | N/A |
| Book Value | 280.47M | 486.93M | 561.37M | 622.04M | 466.04M | 184.01M | 272.92M | 323.00M | 407.19M | 365.40M | N/A | N/A |
| Return on Equity | -0.87 | -0.25 | -0.26 | -0.19 | 0.14 | -0.60 | -0.28 | -0.48 | -0.38 | -0.44 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 51.08M | 21,000 | 2.42M | 4.42M | 2.83M | 2.12M | 970,000 | 132.01M | 50,000 | 316,000 | 84.87M | 4.02M |
| Net Income | 32.72M | (21.59M) | (36.54M) | (125.77M) | (60.20M) | (57.96M) | (59.00M) | 66.89M | (72.24M) | (67.48M) | 21.91M | (54.59M) |
| EPS | 0.61 | -0.40 | -0.68 | -2.34 | -1.12 | -1.08 | -1.10 | 1.24 | -1.34 | -1.26 | 0.41 | -1.03 |
| Free Cash Flow | 28.88M | (23.31M) | (40.58M) | (46.43M) | (53.41M) | (47.81M) | (45.20M) | 15.82M | (73.15M) | (52.59M) | 9.07M | (45.70M) |
| FCF / Share | 0.54 | -0.43 | -0.75 | -0.86 | -0.99 | -0.89 | -0.84 | 0.29 | -1.36 | -0.98 | 0.17 | -0.86 |
| Operating CF | 28.88M | (23.31M) | (40.56M) | (46.34M) | (53.36M) | (47.77M) | (45.19M) | 15.96M | (73.05M) | (51.04M) | 9.52M | (44.93M) |
| Total Assets | 349.89M | 326.80M | 352.63M | 399.07M | 495.34M | 547.11M | 595.25M | 645.57M | 623.19M | 696.38M | 746.92M | 720.65M |
| Total Debt | 7.65M | 13.86M | 9.08M | 9.78M | 10.20M | 10.84M | 11.49M | 12.12M | 12.50M | 11.84M | 10.73M | 3.45M |
| Cash & Equiv | 329.46M | 307.53M | 330.84M | 371.44M | 417.94M | 471.39M | 519.26M | 564.12M | 546.51M | 618.83M | 670.90M | 659.11M |
| Book Value | 312.62M | 280.47M | 294.99M | 324.33M | 437.68M | 486.93M | 534.36M | 581.92M | 502.40M | 561.37M | 617.23M | 581.68M |
| Return on Equity | 0.10 | -0.08 | -0.12 | -0.39 | -0.14 | -0.12 | -0.11 | 0.11 | -0.14 | -0.12 | 0.04 | -0.09 |
